View ValuationSysmex 将来の成長Future 基準チェック /16Sysmex利益と収益がそれぞれ年間10.5%と5.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に10.5% 11%なると予測されています。主要情報10.5%収益成長率11.05%EPS成長率Medical Equipment 収益成長16.0%収益成長率5.6%将来の株主資本利益率10.54%アナリストカバレッジGood最終更新日11 May 2026今後の成長に関する最新情報お知らせ • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.お知らせ • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.すべての更新を表示Recent updatesお知らせ • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026お知らせ • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.お知らせ • Mar 05Sysmex Corporation (TSE:6869) announces an Equity Buyback for 30,000,000 shares, representing 4.81% for ¥30,000 million.Sysmex Corporation (TSE:6869) announces a share repurchase program. Under the program, the company will repurchase up to 30,000,000 shares, representing 4.81% of its issued share capital, for ¥30,000 million. The program will be valid till September 18, 2026. The purpose of the program is to improve capital efficiency and enhance shareholder returns as well as active business investment for our future growth. The purchased shares will be cancelled. As of December 31, 2025, the company had 623,180,031 outstanding shares (excluding treasury stock) and 6,300,045 treasury shares.お知らせ • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.お知らせ • Feb 12Sysmex Corporation Announces Executive and Board Changes, Effective April 1, 2026Sysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 12, 2026, to change the representative directors as stated below. Reasons for Change. To further strengthen management structure in order to enhance corporate value. Iwane Matsui has been newly appointed as the President (Representative Director), while previously serving as Member of the Managing Board and Senior Executive Officer, Senior Managing Director. Kaoru Asano appointed as the Member of the Managing Board, from currently holding the title of President (Representative Director). Effective Date of Transfer: April 1, 2026. Kaoru Asano is scheduled to resign from the Member of the Managing Board at the Ordinary General Meeting of Shareholders to be held in June 2026 and subsequently serve as Senior Executive Advisor. There are no changes to Hisashi Ietsugu's current position as Chairperson and Group CEO. Iwane Matsui was born on January 1, 1961, and graduated from Kobe University with a Bachelor of Faculty of Law in March 1985. He joined TOA Medical Electronics Co. Ltd. (presently Sysmex Corporation) in April 1985. His career progressed through various roles, including serving as President of Sysmex Europe GmbH (presently Sysmex Europe SE) from 2001 to 2005, and later as Executive Vice Chairman & CEO of Sysmex Europe GmbH from 2005 to 2007. He held the position of Executive Vice President of the Customer Support Division from 2007 to 2009, followed by Executive Vice President of the IVD Business Strategy Division from 2009 to 2011. From 2011 to 2013, he served as Executive Officer and Executive Vice President of Corporate Business Planning, and from 2013 to 2015, he was an Executive Officer and Executive Vice President of International Business Management. He then became a Senior Executive Officer from 2017 to 2019, and a Managing Director in 2019. He was appointed as a Member of the Managing Board and Senior Executive Officer in June 2019 and has held the same position since April 2023, also serving as a Senior Managing Director.お知らせ • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.お知らせ • Dec 05Sysmex Corporation to Report Q3, 2026 Results on Feb 12, 2026Sysmex Corporation announced that they will report Q3, 2026 results on Feb 12, 2026お知らせ • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.お知らせ • Sep 04Sysmex Corporation to Report Q2, 2026 Results on Nov 05, 2025Sysmex Corporation announced that they will report Q2, 2026 results on Nov 05, 2025お知らせ • Jun 25+ 1 more updateSysmex America, Inc. Receives FDA Clearance for Automated Blood Coagulation Analyzer CN-6000™?Sysmex America Inc. has received FDA clearance for the CN-6000 Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests: Prothrombin Time (PT) and PT INR with Dade®? Innovin®? Activated Partial Thromboplastin Time (APTT) with Dade®? Actin®? FSL; Fibrinogen (Fbg) with Dade®? Thrombin Reagent; Antithrombin (AT) with INNOVANCE®? Antithrombin; D-dimer with INNOVANCE D-Dimmer. Laboratories with high workloads may opt for the optional sampler that provides an expandable sample loading capacity. Sysmex will continue efforts to obtain market authorization for the Automated Blood Coagulation Analyzer CN-3000 and additional reagent applications.お知らせ • Jun 07Sysmex Corporation to Report Q1, 2026 Results on Aug 06, 2025Sysmex Corporation announced that they will report Q1, 2026 results on Aug 06, 2025お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 27, 2025Sysmex Corporation, Annual General Meeting, Jun 27, 2025.お知らせ • Feb 28Sysmex Corporation to Report Fiscal Year 2025 Results on May 14, 2025Sysmex Corporation announced that they will report fiscal year 2025 results on May 14, 2025お知らせ • Oct 03D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869).D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024. Francesco Stella of Hogan Lovells acted as legal advisor for Sysmex Corporation. D-Group S.p.A. completed the acquisition of an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024.お知らせ • Jun 27+ 2 more updatesSysmex Corporation to Report Q3, 2025 Results on Feb 12, 2025Sysmex Corporation announced that they will report Q3, 2025 results on Feb 12, 2025お知らせ • May 12Sysmex Corporation, Annual General Meeting, Jun 21, 2024Sysmex Corporation, Annual General Meeting, Jun 21, 2024.お知らせ • Mar 08Sysmex Corporation to Report Fiscal Year 2024 Results on May 09, 2024Sysmex Corporation announced that they will report fiscal year 2024 results on May 09, 2024お知らせ • Feb 09Sysmex Corporation Reaffirm Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Sysmex Corporation announced year-end dividend for the fiscal year ending March 31, 2024, with a record date of March 31, 2024, will be paid on the shares before the stock split, because the effective date of the share split is April 1, 2024. The year-end dividend forecast for the fiscal year ending March 31, 2024 remains unchanged from that the announcement on May 11, 2023, which forecasts the year-end dividend of ¥42 per share.お知らせ • Nov 30Sysmex Corporation to Report Q3, 2024 Results on Feb 09, 2024Sysmex Corporation announced that they will report Q3, 2024 results on Feb 09, 2024お知らせ • Sep 08Sysmex Corporation to Report Q2, 2024 Results on Nov 08, 2023Sysmex Corporation announced that they will report Q2, 2024 results on Nov 08, 2023お知らせ • Jun 03Sysmex Corporation to Report Q1, 2024 Results on Aug 08, 2023Sysmex Corporation announced that they will report Q1, 2024 results at 3:00 PM, Tokyo Standard Time on Aug 08, 2023お知らせ • May 13Sysmex Corporation, Annual General Meeting, Jun 23, 2023Sysmex Corporation, Annual General Meeting, Jun 23, 2023.お知らせ • Feb 07Sysmex Corporation Announces Management ChangesSysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 7, 2023, to change the representative directors. Kaoru Asano appointed as President (Representative Director) from Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO. Appointment Date (Scheduled): April 1, 2023. Date of birth: October 19, 1958. Education: Graduate School of Engineering Osaka University, Division of Electronic Engineering. 2021- Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO; 2018-2021 Member of the Managing Board and Senior Executive Officer, Senior Managing Director, COO LS Business Unit and CTO; 2017-2018 Member of the Managing Board and Senior Executive Officer, Senior Managing Director; 2015-2017 Member of the Managing Board and Senior Executive Officer, Managing Director; 2014-2015 Appointed Member of the Managing Board and Senior Executive Officer. 2013-2014 -Appointed Senior Executive Officer, Executive Vice President of Central Research Laboratories; 2011-2013 Appointed Executive Officer, Executive Vice President of R&D Strategic Planning; 2009-2011 Appointed Executive Officer, Executive Vice President of Central Research Laboratories; Aug. 1987 Joined TOA Medical Electronics (presently Sysmex Corporation); Apr. 1983 Joined Kawasaki Heavy Industries Ltd.; March 1983 Graduated from Osaka University. Hisashi Ietsugu: Current: Chairman and CEO (Representative Director); New: Chairman and Group CEO, (Representative Director).お知らせ • Jan 11Sysmex America, Inc. Appoints Chris Cappella as Chief Financial OfficerSysmex America Inc. announced that Chris Cappella has joined the Company as Chief Financial Officer. He will lead Sysmex America's regional finance organization and financial activities including accounting and controllership, financial planning and analysis, tax, internal audit and treasury. to joining Sysmex, Chris held a variety of finance leadership roles at Roche, most recently as the vice president of finance for Core Lab. At Roche, he was instrumental in driving growth through the cross-functional integration of agile strategies. Before his time at Roche, Chris was a finance manager at Brightpoint Inc. He started his career at Ernst & Young and is a Certified Public Accountant.お知らせ • Dec 01Sysmex Corporation to Report Q3, 2023 Results on Feb 09, 2023Sysmex Corporation announced that they will report Q3, 2023 results on Feb 09, 2023業績と収益の成長予測OTCPK:SSMX.F - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2029594,16060,03444,080102,50073/31/2028564,56953,23336,42090,940143/31/2027535,02247,11229,53984,034153/31/2026500,65834,35442,03991,0711512/31/2025502,94544,74827,42979,368N/A9/30/2025498,69146,68623,89776,177N/A6/30/2025502,42847,19127,92279,772N/A3/31/2025508,64353,66938,28788,246N/A12/31/2024501,85157,79036,79483,959N/A9/30/2024491,29153,45532,05083,365N/A6/30/2024478,10552,04920,18470,528N/A3/31/2024461,51049,63913,71463,905N/A12/31/2023438,28445,06317,88467,822N/A9/30/2023429,17843,98124,43571,237N/A6/30/2023419,82446,37532,65676,345N/A3/31/2023410,50245,78426,33068,835N/A12/31/2022403,62246,37710,93047,673N/A9/30/2022389,04945,83913,27149,778N/A6/30/2022370,44642,13014,59847,540N/A3/31/2022363,78044,09326,70558,739N/A12/31/2021352,12642,75538,11470,008N/A9/30/2021341,74442,73245,44172,223N/A6/30/2021323,92538,64836,70663,941N/A3/31/2021305,07333,14233,02058,813N/A12/31/2020295,66631,67532,52057,779N/A9/30/2020291,07229,94324,74150,094N/A6/30/2020293,95132,67327,96955,350N/A3/31/2020301,98034,88326,71053,182N/A12/31/2019303,29638,81321,01450,806N/A9/30/2019300,30239,344N/A52,225N/A6/30/2019296,08538,497N/A49,183N/A3/31/2019293,50641,224N/A44,743N/A12/31/2018287,75637,574N/A47,106N/A9/30/2018287,02239,502N/A48,028N/A6/30/2018286,17740,426N/A45,698N/A3/31/2018281,93539,222N/A52,240N/A12/31/2017271,65739,224N/A49,158N/A9/30/2017262,20736,345N/A41,613N/A6/30/2017252,45139,407N/A41,968N/A3/31/2017249,89940,636N/A32,832N/A12/31/2016248,26541,115N/A33,562N/A9/30/2016250,18442,910N/A37,052N/A6/30/2016254,68338,176N/A37,911N/A3/31/2016253,15736,233N/A39,567N/A12/31/2015251,20933,103N/A38,434N/A9/30/2015244,02830,712N/A38,559N/A6/30/2015232,28028,957N/A37,235N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SSMX.Fの予測収益成長率 (年間10.5% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: SSMX.Fの収益 ( 10.5% ) US市場 ( 16.7% ) よりも低い成長が予測されています。高成長収益: SSMX.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SSMX.Fの収益 ( 5.6% ) US市場 ( 11.6% ) よりも低い成長が予測されています。高い収益成長: SSMX.Fの収益 ( 5.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SSMX.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 10.5 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 22:12終値2026/05/11 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sysmex Corporation 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29 アナリスト機関Masahiro NakanomyoBarclaysKei TakeuchiBofA Global ResearchRitsuo WatanabeBofA Global Research26 その他のアナリストを表示
お知らせ • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.
お知らせ • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.
お知らせ • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026
お知らせ • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.
お知らせ • Mar 05Sysmex Corporation (TSE:6869) announces an Equity Buyback for 30,000,000 shares, representing 4.81% for ¥30,000 million.Sysmex Corporation (TSE:6869) announces a share repurchase program. Under the program, the company will repurchase up to 30,000,000 shares, representing 4.81% of its issued share capital, for ¥30,000 million. The program will be valid till September 18, 2026. The purpose of the program is to improve capital efficiency and enhance shareholder returns as well as active business investment for our future growth. The purchased shares will be cancelled. As of December 31, 2025, the company had 623,180,031 outstanding shares (excluding treasury stock) and 6,300,045 treasury shares.
お知らせ • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.
お知らせ • Feb 12Sysmex Corporation Announces Executive and Board Changes, Effective April 1, 2026Sysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 12, 2026, to change the representative directors as stated below. Reasons for Change. To further strengthen management structure in order to enhance corporate value. Iwane Matsui has been newly appointed as the President (Representative Director), while previously serving as Member of the Managing Board and Senior Executive Officer, Senior Managing Director. Kaoru Asano appointed as the Member of the Managing Board, from currently holding the title of President (Representative Director). Effective Date of Transfer: April 1, 2026. Kaoru Asano is scheduled to resign from the Member of the Managing Board at the Ordinary General Meeting of Shareholders to be held in June 2026 and subsequently serve as Senior Executive Advisor. There are no changes to Hisashi Ietsugu's current position as Chairperson and Group CEO. Iwane Matsui was born on January 1, 1961, and graduated from Kobe University with a Bachelor of Faculty of Law in March 1985. He joined TOA Medical Electronics Co. Ltd. (presently Sysmex Corporation) in April 1985. His career progressed through various roles, including serving as President of Sysmex Europe GmbH (presently Sysmex Europe SE) from 2001 to 2005, and later as Executive Vice Chairman & CEO of Sysmex Europe GmbH from 2005 to 2007. He held the position of Executive Vice President of the Customer Support Division from 2007 to 2009, followed by Executive Vice President of the IVD Business Strategy Division from 2009 to 2011. From 2011 to 2013, he served as Executive Officer and Executive Vice President of Corporate Business Planning, and from 2013 to 2015, he was an Executive Officer and Executive Vice President of International Business Management. He then became a Senior Executive Officer from 2017 to 2019, and a Managing Director in 2019. He was appointed as a Member of the Managing Board and Senior Executive Officer in June 2019 and has held the same position since April 2023, also serving as a Senior Managing Director.
お知らせ • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.
お知らせ • Dec 05Sysmex Corporation to Report Q3, 2026 Results on Feb 12, 2026Sysmex Corporation announced that they will report Q3, 2026 results on Feb 12, 2026
お知らせ • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.
お知らせ • Sep 04Sysmex Corporation to Report Q2, 2026 Results on Nov 05, 2025Sysmex Corporation announced that they will report Q2, 2026 results on Nov 05, 2025
お知らせ • Jun 25+ 1 more updateSysmex America, Inc. Receives FDA Clearance for Automated Blood Coagulation Analyzer CN-6000™?Sysmex America Inc. has received FDA clearance for the CN-6000 Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests: Prothrombin Time (PT) and PT INR with Dade®? Innovin®? Activated Partial Thromboplastin Time (APTT) with Dade®? Actin®? FSL; Fibrinogen (Fbg) with Dade®? Thrombin Reagent; Antithrombin (AT) with INNOVANCE®? Antithrombin; D-dimer with INNOVANCE D-Dimmer. Laboratories with high workloads may opt for the optional sampler that provides an expandable sample loading capacity. Sysmex will continue efforts to obtain market authorization for the Automated Blood Coagulation Analyzer CN-3000 and additional reagent applications.
お知らせ • Jun 07Sysmex Corporation to Report Q1, 2026 Results on Aug 06, 2025Sysmex Corporation announced that they will report Q1, 2026 results on Aug 06, 2025
お知らせ • May 15Sysmex Corporation, Annual General Meeting, Jun 27, 2025Sysmex Corporation, Annual General Meeting, Jun 27, 2025.
お知らせ • Feb 28Sysmex Corporation to Report Fiscal Year 2025 Results on May 14, 2025Sysmex Corporation announced that they will report fiscal year 2025 results on May 14, 2025
お知らせ • Oct 03D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869).D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024. Francesco Stella of Hogan Lovells acted as legal advisor for Sysmex Corporation. D-Group S.p.A. completed the acquisition of an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024.
お知らせ • Jun 27+ 2 more updatesSysmex Corporation to Report Q3, 2025 Results on Feb 12, 2025Sysmex Corporation announced that they will report Q3, 2025 results on Feb 12, 2025
お知らせ • May 12Sysmex Corporation, Annual General Meeting, Jun 21, 2024Sysmex Corporation, Annual General Meeting, Jun 21, 2024.
お知らせ • Mar 08Sysmex Corporation to Report Fiscal Year 2024 Results on May 09, 2024Sysmex Corporation announced that they will report fiscal year 2024 results on May 09, 2024
お知らせ • Feb 09Sysmex Corporation Reaffirm Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Sysmex Corporation announced year-end dividend for the fiscal year ending March 31, 2024, with a record date of March 31, 2024, will be paid on the shares before the stock split, because the effective date of the share split is April 1, 2024. The year-end dividend forecast for the fiscal year ending March 31, 2024 remains unchanged from that the announcement on May 11, 2023, which forecasts the year-end dividend of ¥42 per share.
お知らせ • Nov 30Sysmex Corporation to Report Q3, 2024 Results on Feb 09, 2024Sysmex Corporation announced that they will report Q3, 2024 results on Feb 09, 2024
お知らせ • Sep 08Sysmex Corporation to Report Q2, 2024 Results on Nov 08, 2023Sysmex Corporation announced that they will report Q2, 2024 results on Nov 08, 2023
お知らせ • Jun 03Sysmex Corporation to Report Q1, 2024 Results on Aug 08, 2023Sysmex Corporation announced that they will report Q1, 2024 results at 3:00 PM, Tokyo Standard Time on Aug 08, 2023
お知らせ • May 13Sysmex Corporation, Annual General Meeting, Jun 23, 2023Sysmex Corporation, Annual General Meeting, Jun 23, 2023.
お知らせ • Feb 07Sysmex Corporation Announces Management ChangesSysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 7, 2023, to change the representative directors. Kaoru Asano appointed as President (Representative Director) from Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO. Appointment Date (Scheduled): April 1, 2023. Date of birth: October 19, 1958. Education: Graduate School of Engineering Osaka University, Division of Electronic Engineering. 2021- Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO; 2018-2021 Member of the Managing Board and Senior Executive Officer, Senior Managing Director, COO LS Business Unit and CTO; 2017-2018 Member of the Managing Board and Senior Executive Officer, Senior Managing Director; 2015-2017 Member of the Managing Board and Senior Executive Officer, Managing Director; 2014-2015 Appointed Member of the Managing Board and Senior Executive Officer. 2013-2014 -Appointed Senior Executive Officer, Executive Vice President of Central Research Laboratories; 2011-2013 Appointed Executive Officer, Executive Vice President of R&D Strategic Planning; 2009-2011 Appointed Executive Officer, Executive Vice President of Central Research Laboratories; Aug. 1987 Joined TOA Medical Electronics (presently Sysmex Corporation); Apr. 1983 Joined Kawasaki Heavy Industries Ltd.; March 1983 Graduated from Osaka University. Hisashi Ietsugu: Current: Chairman and CEO (Representative Director); New: Chairman and Group CEO, (Representative Director).
お知らせ • Jan 11Sysmex America, Inc. Appoints Chris Cappella as Chief Financial OfficerSysmex America Inc. announced that Chris Cappella has joined the Company as Chief Financial Officer. He will lead Sysmex America's regional finance organization and financial activities including accounting and controllership, financial planning and analysis, tax, internal audit and treasury. to joining Sysmex, Chris held a variety of finance leadership roles at Roche, most recently as the vice president of finance for Core Lab. At Roche, he was instrumental in driving growth through the cross-functional integration of agile strategies. Before his time at Roche, Chris was a finance manager at Brightpoint Inc. He started his career at Ernst & Young and is a Certified Public Accountant.
お知らせ • Dec 01Sysmex Corporation to Report Q3, 2023 Results on Feb 09, 2023Sysmex Corporation announced that they will report Q3, 2023 results on Feb 09, 2023